

## Pakistan

### Support for Vaccine: Pneumococcal This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b>	Pakistan			
<b>2. Vaccine grant number:</b>	10-PAK-08b-Y, 1115-PAK-12b-X, 16-PAK-12b-X, 1718-PAK-12b-X, 19-PAK-25a-Y, 1920-PAK-12a-X, 2023-PAK-12a-X			
<b>3. Date of Decision Letter:</b>	9/30/2019			
<b>4. Date of the Partnership Framework Agreement:</b>	19-May-15			
<b>5. Programme title:</b>	New Vaccine Support (NVS), Pneumococcal , Routine			
<b>6. Vaccine type:</b>	Pneumococcal			
<b>7. Requested product presentation and formulation of vaccine:</b>	PCV10, 4 dose(s) per vial, LIQUID			
<b>8. Programme Duration:<sup>1</sup></b>	2011-2023			
<b>9. Programme Budget (indicative):<sup>2</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)			
	2011-2019	2020	2021	Total <sup>2</sup>
Programme Budget (US\$)	464,985,761	38,766,000	38,299,500	542,051,261
<b>10. Vaccine introduction grant</b>				
	<b>Approval</b>			
	<b>Year</b>	<b>Grant Number</b>	<b>Amount (US\$)</b>	
	2010	10-PAK-08b-Y	4,839,500	
	<b>Disbursement</b>			
	<b>Disbursement date</b>		<b>Amount (US\$)</b>	
	29 October, 2012		3,056,500	
	26 May, 2011		1,783,000	
<b>11. Product switch grant</b>				
	<b>Approval</b>			
	<i>Approval</i>			
	<b>Year</b>	<b>Grant Number</b>	<b>Amount (US\$)</b>	
	2019	19-PAK-25a-Y	1,768,879	
	<b>Disbursement</b>			
	<b>Disbursement date</b>		<b>Amount (US\$)</b>	
	17 July, 2019		366,156	
	23 July, 2019		1,368,274	

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the amount that Gavi has approved.

**12. Indicative Annual Amounts:**<sup>3</sup> (subject to the terms of the Partnership Framework Agreement, if applicable)

Type of supplies to be purchased with Gavi funds	2012-2019	2020
Number of vaccine doses		11,375,500
Annual Amounts (US\$)	464,985,761	38,766,000

**13. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

**14. Self-procurement:** Not applicable

**15. Co-financing obligations:**

According to the co-financing policy, the Country falls within the group: Preparatory transition phase

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	FY 2020/2021	FY 2021/2022	FY 2022/2023	FY 2023/2024
Number of vaccine doses	5,077,600	6,116,400	7,033,600	8,088,800
Number of AD syringes	5,031,700	6,061,100	6,970,200	8,015,800
Number of re-constitution syringes	-	-	-	-
Number of safety boxes	55,375	66,675	76,700	88,200
Value of vaccine doses (US\$)	15,486,145	18,654,200	21,452,330	24,670,179
Total co-financing payments (US\$) (including freight)	15,841,500	19,099,500	21,964,000	25,259,000

**16. Operational support for campaigns:**  
Not applicable

**17. Additional Reporting Requirements:**

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> </ul>	31 March 2020 15 May 2020

	<ul style="list-style-type: none"> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	
	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
<b>18. Financial clarifications:</b>  Not applicable		
<b>19. Other conditions:</b>  Not applicable		

Signed by,

**On behalf of Gavi**



Thabani Maphosa  
Managing Director, Country Programmes  
30/09/2019